KR20100120971A - 가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 mri 조영제 - Google Patents
가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 mri 조영제 Download PDFInfo
- Publication number
- KR20100120971A KR20100120971A KR1020090039883A KR20090039883A KR20100120971A KR 20100120971 A KR20100120971 A KR 20100120971A KR 1020090039883 A KR1020090039883 A KR 1020090039883A KR 20090039883 A KR20090039883 A KR 20090039883A KR 20100120971 A KR20100120971 A KR 20100120971A
- Authority
- KR
- South Korea
- Prior art keywords
- pullulan
- dtpa
- gadolinium
- gadolinium complex
- contrast agent
- Prior art date
Links
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 title claims abstract description 91
- 229910052688 Gadolinium Inorganic materials 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title description 7
- 229920001218 Pullulan Polymers 0.000 claims abstract description 42
- 239000004373 Pullulan Substances 0.000 claims abstract description 42
- 235000019423 pullulan Nutrition 0.000 claims abstract description 42
- 239000002616 MRI contrast agent Substances 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000003960 organic solvent Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims abstract 9
- RAZLJUXJEOEYAM-UHFFFAOYSA-N 2-[bis[2-(2,6-dioxomorpholin-4-yl)ethyl]azaniumyl]acetate Chemical compound C1C(=O)OC(=O)CN1CCN(CC(=O)O)CCN1CC(=O)OC(=O)C1 RAZLJUXJEOEYAM-UHFFFAOYSA-N 0.000 claims description 30
- 210000004185 liver Anatomy 0.000 claims description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 abstract description 29
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 18
- 230000003902 lesion Effects 0.000 description 17
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000003660 reticulum Anatomy 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- 241000223678 Aureobasidium pullulans Species 0.000 description 1
- 241001480003 Chaetothyriales Species 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 125000006159 dianhydride group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
- A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0018—Pullulan, i.e. (alpha-1,4)(alpha-1,6)-D-glucan; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Abstract
Description
Claims (11)
- 풀루란 및 DTPA(다이에틸렌트리아민펜타아세트산 디안하이드라이드)가 에스테르 결합에 의해 형성된 풀루란-DTPA 접합체에 가돌리늄이 DTPA에 배위결합되어 형성된 가돌리늄 착물.
- 풀루란 및 DTPA를 유기용매 중에 용해하고 반응시켜 풀루란의 히드록시기에 DTPA를 에스테르 결합시켜 풀루란-DTPA 접합체를 제조하는 단계;상기 풀루란-DTPA 접합체의 수용액을 가돌리늄 수용액과 혼합하고 pH를 pH 5-7로 조정하여 가돌리늄 착물을 형성키는 단계를 포함하는,제 1 항 또는 제 2 항에 따른 가돌리늄 착물을 제조하는 방법.
- 제 3 항에 있어서, 풀루란을 1~2.5 X 10-2 mM, DTPA를 5~15 mM의 농도로 반응시키는 것을 특징으로 하는 방법.
- 제 3 항에 있어서, 상기 용매는 디메틸술폭시드(DMSO)인 것을 특징으로 하는 방법.
- 제 3 항에 있어서, 상기 가돌리늄 착물을 형성키는 단계에서 pH 5-7로 조정하여 24시간 이상 유지하는 것을 특징으로 하는 방법.
- 제 1 항 또는 제 2 항에 따른 가돌리늄 착물을 포함하는 MRI 조영제 조성물.
- 제 7 항에 있어서, 간을 진단하기 위한 것을 특징으로 하는 MRI 조영제 조성물.
- 제 7 항에 있어서, 간암을 진단하기 위한 것을 특징으로 하는 MRI 조영제 조성물.
- 제 7 항에 있어서, 정맥주사제인 것을 특징으로 하는 MRI 조영제.
- 제 1 항 또는 제 2 항에 따른 가돌릭늄 착물을 MRI 조영제로서 사용하여 질병의 진단을 위한 정보를 제공하는 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090039883A KR101059285B1 (ko) | 2009-05-07 | 2009-05-07 | 가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 mri 조영제 |
EP10772247.2A EP2447269B1 (en) | 2009-05-07 | 2010-05-04 | Gadolinium complex, method for preparing same, and mri contrast agent comprising same |
US13/319,118 US9072782B2 (en) | 2009-05-07 | 2010-05-04 | Gadolinium complex, method for preparing same, and MRI contrast agent comprising same |
PCT/KR2010/002819 WO2010128787A2 (ko) | 2009-05-07 | 2010-05-04 | 가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 mri 조영제 |
CN201080026113.9A CN102803270B (zh) | 2009-05-07 | 2010-05-04 | 钆配位化合物、其制造方法、以及含有它的mri造影剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090039883A KR101059285B1 (ko) | 2009-05-07 | 2009-05-07 | 가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 mri 조영제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100120971A true KR20100120971A (ko) | 2010-11-17 |
KR101059285B1 KR101059285B1 (ko) | 2011-08-24 |
Family
ID=43050614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090039883A KR101059285B1 (ko) | 2009-05-07 | 2009-05-07 | 가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 mri 조영제 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9072782B2 (ko) |
EP (1) | EP2447269B1 (ko) |
KR (1) | KR101059285B1 (ko) |
CN (1) | CN102803270B (ko) |
WO (1) | WO2010128787A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101293866B1 (ko) * | 2011-09-08 | 2013-08-07 | 성균관대학교산학협력단 | GO-Gd-DTPA 착물, 이의 제조 방법, 및 이것을 포함하는 MRI 조영제 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2663294B1 (en) | 2011-01-11 | 2015-09-30 | Capsugel Belgium NV | New hard capsules comprising pullulan |
CN105566511B (zh) * | 2016-01-27 | 2017-11-03 | 天津医科大学 | 电荷翻转普鲁兰多糖衍生物及其合成方法和用途 |
AU2018251256B2 (en) | 2017-04-14 | 2023-10-05 | Capsugel Belgium Nv | Pullulan capsules |
JP7222911B2 (ja) | 2017-04-14 | 2023-02-15 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ | プルランを作製する方法 |
KR102272741B1 (ko) * | 2019-07-11 | 2021-07-02 | 가톨릭대학교 산학협력단 | 4차원 자기공명 혈관조영술의 영상정보 후처리를 통한 3차원 감산 동맥조영술과 3차원 감산 정맥조영술 및 4차원 컬러 혈관조영술의 동시 구현 방법과 의료영상 시스템 |
CN112940157B (zh) * | 2021-03-22 | 2023-01-10 | 南方医科大学 | 一种钆螯合物及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE465907B (sv) * | 1984-11-01 | 1991-11-18 | Nyegaard & Co As | Diagnosticeringsmedel innehaallande en paramagnetisk metall |
NZ500273A (en) * | 1997-03-18 | 2001-12-21 | Nihon Schering Kabushiki Kaish | Gadolinium (Gd) polymer MRI contrast agent responsive to environmental changes |
CN1317037C (zh) * | 2005-06-06 | 2007-05-23 | 中国人民解放军第二军医大学 | 一种磁共振肿瘤靶向对比剂及其制备方法 |
CN100431614C (zh) * | 2006-06-16 | 2008-11-12 | 中国科学院长春应用化学研究所 | 沙枣胶多糖修饰的顺磁性金属配合物磁共振成像造影剂 |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
US20080182004A1 (en) * | 2007-01-31 | 2008-07-31 | Rosemary Shine Baker | Production of Sheeted Fruit and Vegetable Snacks |
-
2009
- 2009-05-07 KR KR1020090039883A patent/KR101059285B1/ko active IP Right Grant
-
2010
- 2010-05-04 EP EP10772247.2A patent/EP2447269B1/en active Active
- 2010-05-04 WO PCT/KR2010/002819 patent/WO2010128787A2/ko active Application Filing
- 2010-05-04 US US13/319,118 patent/US9072782B2/en active Active
- 2010-05-04 CN CN201080026113.9A patent/CN102803270B/zh active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101293866B1 (ko) * | 2011-09-08 | 2013-08-07 | 성균관대학교산학협력단 | GO-Gd-DTPA 착물, 이의 제조 방법, 및 이것을 포함하는 MRI 조영제 |
US8987429B2 (en) | 2011-09-08 | 2015-03-24 | Research And Business Foundation Sungkyunkwan University | GO-Gd-DTPA complex, preparation method thereof, and MRI contrast agent comprising the same |
Also Published As
Publication number | Publication date |
---|---|
US9072782B2 (en) | 2015-07-07 |
CN102803270A (zh) | 2012-11-28 |
EP2447269A4 (en) | 2015-07-01 |
US20120058054A1 (en) | 2012-03-08 |
KR101059285B1 (ko) | 2011-08-24 |
CN102803270B (zh) | 2015-04-22 |
WO2010128787A3 (ko) | 2011-03-24 |
WO2010128787A9 (ko) | 2011-05-12 |
EP2447269A2 (en) | 2012-05-02 |
EP2447269B1 (en) | 2017-11-01 |
WO2010128787A2 (ko) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101059285B1 (ko) | 가돌리늄 착물, 그 제조방법, 및 그것을 포함하는 mri 조영제 | |
Ye et al. | Targeted biodegradable dendritic MRI contrast agent for enhanced tumor imaging | |
Jia et al. | Active-target T1-weighted MR imaging of tiny hepatic tumor via RGD modified ultra-small Fe3O4 nanoprobes | |
JP2894879B2 (ja) | 診断用造影剤 | |
US20080241073A1 (en) | Polymeric Micelle Type Mri Imaging Agent | |
JPH06511033A (ja) | 共重合体、並びに磁気共鳴画像形成および他の用途におけるコントラスト剤としてのそれらの使用 | |
KR20000076368A (ko) | 미소 환경 변화를 인식하는 mri 조영제 | |
JP2006188683A (ja) | 樹枝状高分子及びその用途 | |
EP3037107B1 (en) | Polymer nanoparticle composite and composition for mri imaging including same | |
JP5651468B2 (ja) | Mri造影能を有する重合体−金属錯体複合体、並びにそれを用いたmri造影用及び/又は抗腫瘍用組成物 | |
WO2014036037A1 (en) | N-boc-dendrimers and their conjugates | |
Zhang et al. | The degradation and clearance of Poly (N-hydroxypropyl-L-glutamine)-DTPA-Gd as a blood pool MRI contrast agent | |
Hapuarachchige et al. | Click chemistry in the development of contrast agents for magnetic resonance imaging | |
Sembo-Backonly et al. | Cyclodextrins: promising scaffolds for MRI contrast agents | |
Ye et al. | A neutral polydisulfide containing Gd (III) DOTA monoamide as a redox‐sensitive biodegradable macromolecular MRI contrast agent | |
Zarabi et al. | HPMA copolymer–doxorubicin–gadolinium conjugates: synthesis, characterization, and in vitro evaluation | |
KR20180135180A (ko) | 요오드를 포함하는 생체적합성 단분자 담도 컴퓨터 단층촬영용 조영제 및 이의 제조방법 | |
JP2901787B2 (ja) | 核磁気共鳴造影剤 | |
JPWO2008059835A1 (ja) | 金属キレート複合体及びプロトン緩和速度増強剤並びにmri造影剤 | |
Zu et al. | PEGylated chitosan grafted with polyamidoamine-dendron as tumor-targeted magnetic resonance imaging contrast agent | |
KR101480393B1 (ko) | 간암 진단을 위한 조영제용 가돌리늄 착물과 이를 이용한 간암 진단용 조영제 | |
KR100368840B1 (ko) | 진단용조영제 | |
JP5320569B2 (ja) | 高分子ミセル及びそれを有効成分として含有する固形がんの診断又は治療剤 | |
JP6182019B2 (ja) | 高分子化造影剤 | |
Ma et al. | Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140818 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150713 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160812 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170726 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180821 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190816 Year of fee payment: 9 |